

Gaurav Shah
51 posts

@gshahrocket
CEO of @RocketPharma. Grammy winner. Follow for insights on healthcare, music & a look into happenings at Rocket. Opinions are my own.



NEWS: Acquisition of Renovacor creates strong synergies by combining key assets including BAG-3 associated DCM, expert teams, capabilities and IP, as well as access to world-leading scientific and clinical collaborators. Learn more: bit.ly/3UrWRcD.




The FDA’s independent advisers voted 15-0 to recommend Bluebird’s eli-cel, a one-time treatment for cerebral adrenoleukodystrophy, a genetic neurological disorder that affects young boys. buff.ly/3aFZ169

Congratulations are in order for our fearless leader, @gshahrocket, who has been named one of The Healthcare Technology Report’s Top 25 Biotech CEOs of 2022! thehealthcaretechnologyreport.com/the-top-25-bio…

Today at #ASH21, we shared positive clinical updates from our Phase 2 registrational trials for Fanconi Anemia and LAD-I and Phase 1 trial for PKD that further illustrate strong progress across our lentiviral vector #genetherapy programs. More: ir.rocketpharma.com/news-releases/…

Our rapid growth continues, & we’re excited to welcome Martin Wilson as General Counsel and Chief Compliance Officer! Martin is an accomplished attorney & industry executive with nearly 20 years of experience across companies of various sizes. Learn more: bit.ly/3DAuQ9j

This year has been gratifying for the growing Rocket family. We’re thankful for a lot, and especially for the opportunity to collaborate with global experts and the rare disease community to seek #genetherapy cures for Danon disease, LAD-I, Fanconi Anemia, PKD and IMO.

We are thrilled to announce updated data in our AAV #genetherapy program in #DanonDisease showing clinical, functional and biomarker improvements at one year or beyond and a manageable safety profile at the low-dose. Learn more: ir.rocketpharma.com/news-releases/… #AHA21



